quadraScope
quadraScope Ventures is an early-stage venture capital firm founded in 2022 and based in Boston with a Tel Aviv presence, investing in longevity biotechnology companies developing therapeutics, diagnostics, and devices for biological age reversal, supported by a Scientific Advisory Board of leading aging researchers.
- Company typePrivate
- Founded2022
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What quadraScope does
quadraScope Ventures is an early-stage venture capital firm founded in 2022 and headquartered in Boston, Massachusetts, with a strategic presence in Tel Aviv, Israel. The firm invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. Its investment thesis is grounded in the Hallmarks of Aging framework introduced by López-Otín et al., and it deploys capital across longevity biotech approaches including senolytics, cellular reprogramming, gene therapy, mitochondrial health, regenerative medicine, and biomarker platforms.
The firm's operating team is small — Managing Partner Fiona Miller, Scientific Director José Navarro-Betancourt, and Financial Analyst Eve Voronkina — and is augmented by a Scientific Advisory Board of globally recognized longevity researchers (Nir Barzilai, Aubrey de Grey, Carmela Abraham, Robert Cargill, Diane Seimetz, Reason, Nikola Markov, Shailesh Chavan) and a Business Advisory Board of operators and investors (Miri Polachek, Nico Helling, Frank Wellens, Daniel Fylstra, Lan Clark, José Cordeiro, Noriko Yokoi). Its portfolio spans approximately 11 companies, including Immunis (stem cell secretome for muscle atrophy), BioChange (regenerative collagen), Alden Scientific (ML-based personalized medicine), Matter Bio (DNA repair), Deciduous Therapeutics (senolytics), Repair Biotechnologies (cholesterol degradation), Vincere Bio (mitochondrial health), Cosmica Bio (organoids), Healthy Longevity Clinic, Advantag Therapeutics (Klotho gene therapy), and BIOIO (lipid metabolism).
As a venture fund, quadraScope generates revenue through traditional fund economics: management fees (typically 2% of committed capital) and carried interest (typically 20% of profits above a hurdle) on successful portfolio exits. Capital is distributed via direct equity investments in early-stage companies; deal sourcing is supported through industry conferences (JPM Healthcare Week, Longevity Nation, RESI Boston), a YouTube interview channel with longevity KOLs, and engagement with scientific community in the Boston-Tel Aviv corridor. No fund size, AUM, or revenue figures have been publicly disclosed.
quadraScope firmographics
Firmographics- Name
- quadraScope
- Legal name
- quadraScope Ventures
- Website
- https://quadrascope.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- quadraScope Ventures is an early-stage venture capital firm founded in 2022 and based in Boston with a Tel Aviv presence, investing in longevity biotechnology companies developing therapeutics, diagnostics, and devices for biological age reversal, supported by a Scientific Advisory Board of leading aging researchers.
- Ownership category
- akta.pro rank
quadraScope industry classification
Industry- Product category
- Venture Capital - Longevity Biotechnology
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where quadraScope is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
quadraScope business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Venture Capital Fund Management: Generates returns through equity investments in early-stage longevity biotechnology companies. Revenue derived from management fees and carried interest (performance fees) on successful exits.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
quadraScope product offering
Product offeringCore offering
quadraScope Ventures is a venture capital firm that invests in early-stage healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. The firm manages capital and deploys equity into longevity biotechnology startups, provides strategic guidance and scientific due diligence, and supports portfolio companies in clinical development and regulatory pathways. Revenue is generated through management fees and carried interest on successful exits.
Product overview
quadraScope Ventures is a venture capital firm that invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices enabling disease treatment and prevention through biological age reversal. As an investment fund, quadraScope does not offer products or services to end customers in the traditional sense. The company focuses on identifying and funding early-stage longevity biotechnology companies across various approaches including senolytics, cellular reprogramming, gene therapy, mitochondrial health, and regenerative medicine. The firm's portfolio includes investments in companies such as Immunis, BioChange, Aldens Scientific, MatterBio, Deciduous Therapeutics, Repair Biotechnologies, Vincere Bio, Cosmica, Healthy Longevity Clinic, AdvantAge Therapeutics, and BIOIO. The investment strategy is grounded in the Hallmarks of Aging scientific framework.
Differentiator
Problem solved
Functional benefit
Products and services
- quadraScope Ventures Investment Fund Early-stage venture capital fund that provides equity capital, scientific due diligence, and strategic support to longevity biotechnology startups developing treatments targeting the Hallmarks of Aging. Limited partners commit capital; returns generated through exits.
Quantifiable outcome
- 12x return on octoScope exit
Companies that use quadraScope
Customer profileNamed customers11 records
Segments1 record
Ideal customer profiles1 record
quadraScope technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
quadraScope partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered portfolio company, strategic and industry.
- Klogenixportfolio companyPortfolio company developing gene therapy using Klotho protein to treat aging and Alzheimer's disease. Co-founded by Carmela Abraham, PhD, who serves on quadraScope's Scientific Advisory Board and discovered that Klotho protein levels decrease with age and are neuroprotective.
- SENS Research FoundationstrategicBiomedical research charity focused on repairing molecular and cellular damage of aging. Scientific founder Aubrey de Grey serves on quadraScope's Scientific Advisory Board. SENS approach aligns with quadraScope's investment thesis on addressing hallmarks of aging.
- Longevity Escape Velocity FoundationstrategicFoundation led by Aubrey de Grey working on rejuvenation research. President & CSO noted that quadraScope encouraged formation of rejuvenation clinics and has been active in defining treatment protocols as strategic pillar alongside clinical trials.
- Immunisportfolio companyPortfolio company developing immune system restoration for muscle building, fat reduction, and treating obesity. Chairman Hans Keirstead cited strategic alignment with quadraScope's vision of extending lifespan and healthspan while treating diseases.
- Healthy Longevity Clinicportfolio companyPortfolio company operating franchise of clinics specializing in personalized rejuvenation treatments and offshore clinical trials. CEO Petr Sramek serves on quadraScope's Business Advisory Board.
- Repair Biotechnologiesportfolio companyPortfolio company developing cholesterol degradation platform to reverse atherosclerosis and fatty liver disease. Co-founder Reason serves on quadraScope's Scientific Advisory Board and is a long-standing investor in longevity industry.
- Biomarkers of Aging ConsortiumindustryConsortium established to develop reliable biomarkers of aging for identification and validation of longevity interventions. quadraScope presented posters at 2023 Biomarkers of Aging Symposium.
- Longevity Biotechnology AssociationindustryIndustry association for longevity biotechnology companies. quadraScope nominated to join in November 2022.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
quadraScope competitors and assessment
Company assessmentDirect peers
- Apollo Health Ventures: Early-stage VC investing specifically in longevity and aging biotech, mirroring quadraScope's thesis on hallmarks-of-aging interventions.
- Kizoo Technology Ventures: Germany-based seed investor dedicated to rejuvenation biotech startups, directly comparable in stage and longevity focus.
- LongeVC: Early-stage venture fund backing longevity and biotech founders, sharing quadraScope's specialist focus and stage.
- Longevity Vision Fund: Sergey Young's fund investing in technologies that extend healthy human lifespan, directly overlapping quadraScope's sector thesis.
- Methuselah Fund: Mission-driven fund investing in companies extending healthspan, closely aligned with quadraScope's rejuvenation focus.
- Age1: Seed-stage fund and accelerator (successor to The Longevity Fund) focused on aging biology startups, a direct longevity-specialist peer.
- R42 Group: AI and longevity-focused venture fund backing aging and healthspan startups, overlapping quadraScope's investment domain.
Regional players
- Maximon: Swiss longevity company builder and investor in healthy-aging ventures; comparable thesis but centered in Europe.
Emerging players
- Cambrian Biopharma: Builds and funds a portfolio of aging-disease therapeutics companies, overlapping quadraScope's longevity portfolio approach via a different (build) model.
Broad incumbents
- Juvenescence: Larger longevity-focused company builder and investor developing aging therapeutics, operating broadly across the same rejuvenation space as quadraScope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
quadraScope social profiles
Digital presencequadraScope financial estimates
Financial estimateRevenue estimate
Valuation estimate
quadraScope leadership team
Management profileNumber of profiles
Profiles18 records
quadraScope funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
quadraScope M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about quadraScope
What does quadraScope do?
quadraScope Ventures is a venture capital firm that invests in early-stage healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. The firm manages capital and deploys equity into longevity biotechnology startups, provides strategic guidance and scientific due diligence, and supports portfolio companies in clinical development and regulatory pathways. Revenue is generated through management fees and carried interest on successful exits.
Is quadraScope a public or private company?
quadraScope is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was quadraScope founded?
quadraScope was founded in 2022. It employs 1 to 10 people.
Where is quadraScope based?
quadraScope is headquartered in Boston, United States, in the North America region.
How does quadraScope make money?
One revenue line is on record: venture Capital Fund Management.
Who are quadraScope's main competitors?
Direct peers on record are Apollo Health Ventures, Kizoo Technology Ventures, LongeVC, Longevity Vision Fund, Methuselah Fund, Age1 and R42 Group. Maximon is listed as a regional player. Cambrian Biopharma is listed as an emerging player. Juvenescence is listed as a broad incumbent.
Does quadraScope have an API?
No public API is recorded for quadraScope.
What industry is quadraScope in?
quadraScope's product category is Venture Capital - Longevity Biotechnology. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.